Cell News and Research

RSS

New stem cell lines help study genetic, biological underpinnings of bipolar disorder

New stem cell lines developed from the skin of adults living with bipolar disorder are providing researchers at the University of Michigan Health System an unprecedented opportunity to delve into the genetic and biological underpinnings of the devastating mood disorder.

24 Aug 2011

New fertilized cells narrowly avoid degenerating into fatal chaos

Research based at Princeton University has revealed that newly fertilized cells only narrowly avoid degenerating into fatal chaos. At the same time, scientists have discovered that embryos have acquired a mechanism to contain this dangerous instability, a finding that could help biologists unravel other mysteries about the first hours of life.

24 Aug 2011

Adapted version of Bailli-re's Nurses' Dictionary for Malaysian students

Elsevier, a leading provider of scientific, technical and medical information products and services announced today that nursing students in Malaysia can look forward to better understanding medical terms with the adaptation of the popular Bailli-re's Nurses' Dictionary.

24 Aug 2011

Scientists show how scaling works in developing fruit fly wings

Weizmann Institute scientists have added a significant piece to the puzzle of scaling - how patterns stay in sync with size as an embryo or organism grows and develops. In a new study appearing in Current Biology, Institute scientists Profs.

24 Aug 2011

Nickel nanoparticles activate cellular pathway that contributes to cancer in lung cells

All the excitement about nanotechnology comes down to this: Structures of materials at the scale of billionths of a meter take on unusual properties. Technologists often focus on the happier among these newfound capabilities, but new research by an interdisciplinary team of scientists at Brown University finds that nanoparticles of nickel activate a cellular pathway that contributes to cancer in human lung cells.

24 Aug 2011

First North American clinical trial to test adult MSC transplantation as a new MS therapy

A team of researchers at three landmark Cleveland institutions have come together to launch a new clinical trial of an experimental treatment for multiple sclerosis.

24 Aug 2011

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

Trophos awarded US patent covering use of novel cardioprotective compound

Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos’ TRO40303 to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).

23 Aug 2011

Seattle genetics new blood cancer drug Adcetris comes with a hefty price tag

Seattle Genetics Inc's new blood cancer drug Adcetris is will come with a price tag of $100,000 for a course of treatment. The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin's lymphoma since 1977.

23 Aug 2011

Seeing provides the big picture, but exploration burns it into memory

Seeing and exploring both are necessary for stability in a person's episodic memory when taking in a new experience, say University of Oregon researchers.

23 Aug 2011

Hutchinson Center to participate in NCI-funded proteome research consortium

The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.

23 Aug 2011

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

itm FlowMedical GmbH announced the start of OPEN-188 clinical trial. It will compare itm Rhenium-PTA, a therapy for the prevention of restenosis in peripheral vessels, to a regular PTA, the standard therapy for the treatment of PAOD.

23 Aug 2011

KalVista raises £8 million in series A round of funding

KalVista Pharmaceuticals, a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.

23 Aug 2011

KU researcher investigates impact of joblessness on masculinity

The acute economic downturn that began in 2008 sometimes is called the "mancession" to reflect its harsher impact on men than women. As recently as last November, 10.4 percent of adult men were unemployed as compared to 8 percent of adult women.

23 Aug 2011

Molecular Endocrinology journal publishes two studies on estrogen hormones

University of Houston (UH) researchers have their sights set on developing possible treatments for breast and colon cancer.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011